Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0000000000213350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
: Welcoming a New Member of the Family of Journals.
Neurology
February 2025
Department of Neurology, Georgetown University School of Medicine, Washington, DC.
Social care reform is welcome, but success will rely on political commitment.
BMJ
January 2025
Health Foundation, London, UK.
ExerG - an exergame-based training device for the rehabilitation of older adults: a functional model usability study.
BMC Geriatr
December 2024
Research Department, Reha Rheinfelden, Rheinfelden, Switzerland.
Background: Exergames are interactive technology-based exercise programs. By combining physical and cognitive training components, they aim to preserve independence in older adults and reduce their risk of falling. This study explored whether primary end users (PEU, healthy older adults and patients with neurological and geriatric diagnoses) and secondary end users (SEU, health professionals) evaluated the ExerG functional model to be usable, providing a positive experience and therefore acceptable.
View Article and Find Full Text PDFPatients' Experiences of Person-Centered Care in the Context of Allogenic Stem Cell Transplantation.
Clin Nurs Res
December 2024
Karolinska Institutet, Stockholm, Sweden.
Studies addressing patients' experiences of person-centered care (PCC) in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are scarce; hence, this study aimed to explore patients' experiences of PCC, and its associations with individual characteristics and health-related quality of life, in the context of allogeneic stem cell transplantation. It is a cross-sectional survey study, in patients who had undergone an allo-HSCT at one center in Sweden. The PCC instrument for outpatient care in rheumatology (PCCoc/rheum) was used.
View Article and Find Full Text PDFSubretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases.
Am J Ophthalmol
December 2024
University of California, Irvine Gavin Herbert Eye Institute; Irvine, CA, USA.
Objective: This review article discusses investigational subretinal gene therapies for retinal vascular diseases, including AVA-101, an adeno-associated viral (AAV) 2 vector expressing soluble vascular endothelial growth factor (VEGF) receptor 1, ABBV-RGX-314, an AAV8 vector expressing an anti-VEGF-A antibody fragment, and EXG102-031, an AAV8 vector expressing a recombinant protein that blocks VEGF family members and angiopoietin 2.
Design: Review article CONCLUSION: Subretinal injection is a commonly used delivery route for investigational gene therapy agents which is theorized to provide relative immune privilege, thereby reducing the risk of inflammation, while providing high transgene expression in photoreceptors and retinal pigment epithelium. Subretinal injection of AVA-101 demonstrated safety and tolerability in Phase I and IIa trials, but failed to maintain visual acuity and control exudation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!